Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

v3.20.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
3 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Operating expenses:    
Research and development $ 1,731,200 $ 4,313,900
General and administrative 1,390,600 1,910,100
Total operating expenses 3,121,800 6,224,000
Loss from operations (3,121,800) (6,224,000)
Other income (expenses), net:    
Interest income (expense), net (3,200) 16,500
Other income 600 0
Loss before income taxes (3,124,400) (6,207,500)
Income taxes (2,400) (2,400)
Net loss and comprehensive loss (3,126,800) (6,209,900)
Accrued dividends on Series B Preferred stock (335,800) (302,500)
Net loss attributable to common stockholders $ (3,462,600) $ (6,512,400)
Basic and diluted net loss attributable to common stockholders per common share $ (.07) $ (.15)
Weighted average shares used in computing basic and diluted net loss attributable to common stockholders per common share 51,321,355 42,622,965